Document is current
Any future updates will be listed below
-
Authors
Gustafsson, Stefan https://orcid.org/0000-0001-5894-0351
Ribeiro, Antônio H. https://orcid.org/0000-0003-3632-8529
Gedon, Daniel
Abreu, Petrus E. O. G. B.
Pielawski, Nicolas
Paixão, Gabriela M. M.
Gutierrez, Marco Antonio https://orcid.org/0000-0003-0964-6222
Krieger, José Eduardo https://orcid.org/0000-0001-5464-1792
Dias, Felipe Meneguitti https://orcid.org/0000-0001-7778-4606
P. Ribeiro, Antonio Luiz https://orcid.org/0000-0002-2740-0042
Lindholm, Daniel https://orcid.org/0000-0003-3526-0614
Schön, Thomas B.
Sundström, Johan https://orcid.org/0000-0003-2247-8454
- License Information
-
More Information
Article History
Received: 24 July 2025
Accepted: 28 April 2026
First Online: 13 May 2026
Competing interests
: The authors declare the following competing interests: J.S. reports direct or indirect stock ownership in companies (Anagram kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) providing services to companies and authorities in the health sector including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, WeMind. AHR reports acting as consultant to Einthoven Technologia LTDA, with vesting options. The remaining authors declare no competing interests.
